Review



leucovorin calcium  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    MedChemExpress leucovorin calcium
    Treatment with D. desulfuricans significantly diminished the anticancer efficacy of the FOLFOX regimen. (a) The in vivo experimental design of this study. 1 × 10 6 MC38 cells were subcutaneously injected into the lateral flank of the mice. D. Desulfuricans were delivered via gavage at a dose of 1 × 10 9 colony-forming units (CFU) per mouse every other day. FOLFOX chemotherapy was administered according to the dosages of oxaliplatin (6 mg/kg), 5-FU (50 mg/kg), and <t>calcium</t> <t>folinate</t> (90 mg/kg), with oxaliplatin administered 2 h after 5-FU once a week via intraperitoneal injection. (b) QPCR was used to compare the absolute abundance of D. desulfuricans in mouse faecal samples before and 7 days after oral administration (n = 24 mice/group). (c, e, and f) Comparison of tumour volumes among groups (n = 6 mice/group). (d) Changes in body weight of mice during the treatment period (n = 6 mice/group). (g) Comparison of tumour weights among different groups (n = 6 mice/group). (h) Histological images of tumour tissues stained with H&E and IHC staining for Ki-67 expression in various groups (scale bar, 100 μm). The results are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, ∗∗∗∗p < 0.001. Statistical significance was determined using one-way ANOVA and Tukey's test for multiple comparisons.
    Leucovorin Calcium, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/leucovorin calcium/product/MedChemExpress
    Average 92 stars, based on 6 article reviews
    leucovorin calcium - by Bioz Stars, 2026-02
    92/100 stars

    Images

    1) Product Images from "Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3"

    Article Title: Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3

    Journal: eBioMedicine

    doi: 10.1016/j.ebiom.2024.105041

    Treatment with D. desulfuricans significantly diminished the anticancer efficacy of the FOLFOX regimen. (a) The in vivo experimental design of this study. 1 × 10 6 MC38 cells were subcutaneously injected into the lateral flank of the mice. D. Desulfuricans were delivered via gavage at a dose of 1 × 10 9 colony-forming units (CFU) per mouse every other day. FOLFOX chemotherapy was administered according to the dosages of oxaliplatin (6 mg/kg), 5-FU (50 mg/kg), and calcium folinate (90 mg/kg), with oxaliplatin administered 2 h after 5-FU once a week via intraperitoneal injection. (b) QPCR was used to compare the absolute abundance of D. desulfuricans in mouse faecal samples before and 7 days after oral administration (n = 24 mice/group). (c, e, and f) Comparison of tumour volumes among groups (n = 6 mice/group). (d) Changes in body weight of mice during the treatment period (n = 6 mice/group). (g) Comparison of tumour weights among different groups (n = 6 mice/group). (h) Histological images of tumour tissues stained with H&E and IHC staining for Ki-67 expression in various groups (scale bar, 100 μm). The results are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, ∗∗∗∗p < 0.001. Statistical significance was determined using one-way ANOVA and Tukey's test for multiple comparisons.
    Figure Legend Snippet: Treatment with D. desulfuricans significantly diminished the anticancer efficacy of the FOLFOX regimen. (a) The in vivo experimental design of this study. 1 × 10 6 MC38 cells were subcutaneously injected into the lateral flank of the mice. D. Desulfuricans were delivered via gavage at a dose of 1 × 10 9 colony-forming units (CFU) per mouse every other day. FOLFOX chemotherapy was administered according to the dosages of oxaliplatin (6 mg/kg), 5-FU (50 mg/kg), and calcium folinate (90 mg/kg), with oxaliplatin administered 2 h after 5-FU once a week via intraperitoneal injection. (b) QPCR was used to compare the absolute abundance of D. desulfuricans in mouse faecal samples before and 7 days after oral administration (n = 24 mice/group). (c, e, and f) Comparison of tumour volumes among groups (n = 6 mice/group). (d) Changes in body weight of mice during the treatment period (n = 6 mice/group). (g) Comparison of tumour weights among different groups (n = 6 mice/group). (h) Histological images of tumour tissues stained with H&E and IHC staining for Ki-67 expression in various groups (scale bar, 100 μm). The results are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, ∗∗∗∗p < 0.001. Statistical significance was determined using one-way ANOVA and Tukey's test for multiple comparisons.

    Techniques Used: In Vivo, Injection, Comparison, Staining, Immunohistochemistry, Expressing



    Similar Products

    leucovorin calcium  (MedChemExpress)
    92
    MedChemExpress leucovorin calcium
    Treatment with D. desulfuricans significantly diminished the anticancer efficacy of the FOLFOX regimen. (a) The in vivo experimental design of this study. 1 × 10 6 MC38 cells were subcutaneously injected into the lateral flank of the mice. D. Desulfuricans were delivered via gavage at a dose of 1 × 10 9 colony-forming units (CFU) per mouse every other day. FOLFOX chemotherapy was administered according to the dosages of oxaliplatin (6 mg/kg), 5-FU (50 mg/kg), and <t>calcium</t> <t>folinate</t> (90 mg/kg), with oxaliplatin administered 2 h after 5-FU once a week via intraperitoneal injection. (b) QPCR was used to compare the absolute abundance of D. desulfuricans in mouse faecal samples before and 7 days after oral administration (n = 24 mice/group). (c, e, and f) Comparison of tumour volumes among groups (n = 6 mice/group). (d) Changes in body weight of mice during the treatment period (n = 6 mice/group). (g) Comparison of tumour weights among different groups (n = 6 mice/group). (h) Histological images of tumour tissues stained with H&E and IHC staining for Ki-67 expression in various groups (scale bar, 100 μm). The results are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, ∗∗∗∗p < 0.001. Statistical significance was determined using one-way ANOVA and Tukey's test for multiple comparisons.
    Leucovorin Calcium, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/leucovorin calcium/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    leucovorin calcium - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier
    rrv cf  (MedChemExpress)
    92
    MedChemExpress rrv cf
    Treatment with D. desulfuricans significantly diminished the anticancer efficacy of the FOLFOX regimen. (a) The in vivo experimental design of this study. 1 × 10 6 MC38 cells were subcutaneously injected into the lateral flank of the mice. D. Desulfuricans were delivered via gavage at a dose of 1 × 10 9 colony-forming units (CFU) per mouse every other day. FOLFOX chemotherapy was administered according to the dosages of oxaliplatin (6 mg/kg), 5-FU (50 mg/kg), and <t>calcium</t> <t>folinate</t> (90 mg/kg), with oxaliplatin administered 2 h after 5-FU once a week via intraperitoneal injection. (b) QPCR was used to compare the absolute abundance of D. desulfuricans in mouse faecal samples before and 7 days after oral administration (n = 24 mice/group). (c, e, and f) Comparison of tumour volumes among groups (n = 6 mice/group). (d) Changes in body weight of mice during the treatment period (n = 6 mice/group). (g) Comparison of tumour weights among different groups (n = 6 mice/group). (h) Histological images of tumour tissues stained with H&E and IHC staining for Ki-67 expression in various groups (scale bar, 100 μm). The results are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, ∗∗∗∗p < 0.001. Statistical significance was determined using one-way ANOVA and Tukey's test for multiple comparisons.
    Rrv Cf, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rrv cf/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    rrv cf - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier
    leucovorin  (MedChemExpress)
    92
    MedChemExpress leucovorin
    Treatment with D. desulfuricans significantly diminished the anticancer efficacy of the FOLFOX regimen. (a) The in vivo experimental design of this study. 1 × 10 6 MC38 cells were subcutaneously injected into the lateral flank of the mice. D. Desulfuricans were delivered via gavage at a dose of 1 × 10 9 colony-forming units (CFU) per mouse every other day. FOLFOX chemotherapy was administered according to the dosages of oxaliplatin (6 mg/kg), 5-FU (50 mg/kg), and <t>calcium</t> <t>folinate</t> (90 mg/kg), with oxaliplatin administered 2 h after 5-FU once a week via intraperitoneal injection. (b) QPCR was used to compare the absolute abundance of D. desulfuricans in mouse faecal samples before and 7 days after oral administration (n = 24 mice/group). (c, e, and f) Comparison of tumour volumes among groups (n = 6 mice/group). (d) Changes in body weight of mice during the treatment period (n = 6 mice/group). (g) Comparison of tumour weights among different groups (n = 6 mice/group). (h) Histological images of tumour tissues stained with H&E and IHC staining for Ki-67 expression in various groups (scale bar, 100 μm). The results are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, ∗∗∗∗p < 0.001. Statistical significance was determined using one-way ANOVA and Tukey's test for multiple comparisons.
    Leucovorin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/leucovorin/product/MedChemExpress
    Average 92 stars, based on 1 article reviews
    leucovorin - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Treatment with D. desulfuricans significantly diminished the anticancer efficacy of the FOLFOX regimen. (a) The in vivo experimental design of this study. 1 × 10 6 MC38 cells were subcutaneously injected into the lateral flank of the mice. D. Desulfuricans were delivered via gavage at a dose of 1 × 10 9 colony-forming units (CFU) per mouse every other day. FOLFOX chemotherapy was administered according to the dosages of oxaliplatin (6 mg/kg), 5-FU (50 mg/kg), and calcium folinate (90 mg/kg), with oxaliplatin administered 2 h after 5-FU once a week via intraperitoneal injection. (b) QPCR was used to compare the absolute abundance of D. desulfuricans in mouse faecal samples before and 7 days after oral administration (n = 24 mice/group). (c, e, and f) Comparison of tumour volumes among groups (n = 6 mice/group). (d) Changes in body weight of mice during the treatment period (n = 6 mice/group). (g) Comparison of tumour weights among different groups (n = 6 mice/group). (h) Histological images of tumour tissues stained with H&E and IHC staining for Ki-67 expression in various groups (scale bar, 100 μm). The results are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, ∗∗∗∗p < 0.001. Statistical significance was determined using one-way ANOVA and Tukey's test for multiple comparisons.

    Journal: eBioMedicine

    Article Title: Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3

    doi: 10.1016/j.ebiom.2024.105041

    Figure Lengend Snippet: Treatment with D. desulfuricans significantly diminished the anticancer efficacy of the FOLFOX regimen. (a) The in vivo experimental design of this study. 1 × 10 6 MC38 cells were subcutaneously injected into the lateral flank of the mice. D. Desulfuricans were delivered via gavage at a dose of 1 × 10 9 colony-forming units (CFU) per mouse every other day. FOLFOX chemotherapy was administered according to the dosages of oxaliplatin (6 mg/kg), 5-FU (50 mg/kg), and calcium folinate (90 mg/kg), with oxaliplatin administered 2 h after 5-FU once a week via intraperitoneal injection. (b) QPCR was used to compare the absolute abundance of D. desulfuricans in mouse faecal samples before and 7 days after oral administration (n = 24 mice/group). (c, e, and f) Comparison of tumour volumes among groups (n = 6 mice/group). (d) Changes in body weight of mice during the treatment period (n = 6 mice/group). (g) Comparison of tumour weights among different groups (n = 6 mice/group). (h) Histological images of tumour tissues stained with H&E and IHC staining for Ki-67 expression in various groups (scale bar, 100 μm). The results are presented as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, ∗∗∗∗p < 0.001. Statistical significance was determined using one-way ANOVA and Tukey's test for multiple comparisons.

    Article Snippet: Oxaliplatin was purchased from Hengrui (Jiangsu, China), 5-fluorouracil injection was obtained from Jinyao (Tianjin, China), and leucovorin calcium from MedChem Express (New Jersey, USA).

    Techniques: In Vivo, Injection, Comparison, Staining, Immunohistochemistry, Expressing